Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 15;10(8):446-453.
doi: 10.4239/wjd.v10.i8.446.

Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future

Hakan Dogruel  1 , Mustafa Kemal Balci  2
Affiliations
Review

Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future

Hakan Dogruel et al. World J Diabetes. .

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It's estimated that 451 million people had diabetes in 2017. As the pathophysiology was understood over the years, treatment options for diabetes increased. Incretin-based therapy is one of them. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) not only significantly lower glucose level with minimal risk of hypoglycemia but also, they have an important advantage in themanagement of cardiovascular risk and obesity. Thus, we will review here GLP-1 RAsrole in the treatment of diabetes.

Keywords: Dipeptidyl peptidase-4 inhibitor; Glucagon-like peptide-1 receptor agonist; Incretin mimetics; Incretin-basedtherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest.

References

    1. Powers AC. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill, 2015
    1. PolonskyKS, BurantCF . In: Shlomo Melmed KS, Polonsky PR, Larsen HM. Kronenberg Williams Textbook of Endocrinology. 13th ed. 2016
    1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795. - PMC - PubMed
    1. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels: International Diabetes Federation, 2017
    1. Porte D, Jr, Pupo AA. Insulin responses to glucose: evidence for a two pool system in man. J Clin Invest. 1969;48:2309–2319. - PMC - PubMed